☆ 4.7 Letter

A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation

ANNALS OF ONCOLOGY (2012)

Journal

ANNALS OF ONCOLOGY

Volume 23, Issue 12, Pages 3188-3189

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mds525

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Medicine, General & Internal

A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report

Tao Zhou, Qiang Xiong, Chen Hong, Qian Wang, Wenxian Wang, Chunwei Xu, Jing Cai

Summary: This study reported a case of a rare EGFR mutation in a non-small cell lung cancer patient and demonstrated the effectiveness of the second-generation EGFR tyrosine kinase inhibitor dacomitinib. The study suggests that dacomitinib may be effective in patients with uncommon EGFR mutations, and next-generation sequencing is recommended as a guiding tool for the treatment of advanced non-small cell lung cancer.

MEDICINE (2022)

Add to Collection

Review Oncology

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations

Jia Li Low, Sun Min Lim, Jii Bum Lee, Byoung Chul Cho, Ross A. Soo

Summary: EGFR mutation is a key oncogenic mutation in non-small-cell lung cancer with adenocarcinoma histology, with Exon 19 deletions and exon 21 L858R substitutions being the most common. EGFR exon 20 insertions, accounting for 4-10% of EGFR mutations, are associated with decreased sensitivity to EGFR tyrosine kinase inhibitors. Approval of amivantamab and mobocertinib represents a significant advancement in the treatment of patients with EGFR exon 20 insertions after chemotherapy failure.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study

Balazs Gieszer, Zsolt Megyesfalvi, Viktoria Dulai, Judit Papay, Ilona Kovalszky, Jozsef Timar, Janos Fillinger, Tunde Harko, Orsolya Pipek, Vanda Teglasi, Eszter Regos, Gergo Papp, Zoltan Szallasi, Viktoria Laszlo, Ferenc Renyi-Vamos, Gabriella Galffy, Csaba Bodor, Balazs Dome, Judit Moldvay

Summary: This study suggests that high EGFR-aVAF in tumoral tissue predicts benefit from EGFR-TKI treatment in advanced LADC, and that exon 19 EGFR mutation is associated with high EGFR-aVAF and improved survival outcomes.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion

Yunfen Zu, Yan Luo, Chongyang Li, Juan Zhao, Tingting He, Xiaoliang Shi, Xin Li

Summary: Thymic carcinoma is a rare and poor prognostic disease, with surgery being the main treatment for early cases and a lack of effective treatment for advanced cases. Molecular and mutational analysis can guide treatment decisions. Tyrosine kinase inhibitors may be an effective treatment strategy for thymic carcinoma patients with EGFR alterations.

JOURNAL OF GENE MEDICINE (2021)

Add to Collection

Article Oncology

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases

Liang Shi, Junfang Tang, Hong Tao, Lili Guo, Weihua Wu, Hongbo Wu, Zichen Liu, Li Tong, Wei Wu, Hongxia Li, Qiyi Meng, Liyan Xu, Nanying Che, Zhe Liu

Summary: The study demonstrates the feasibility of detecting EGFR mutations in cerebrospinal fluid and plasma. In patients with brain metastases from LADC, cerebrospinal fluid can serve as a liquid biopsy specimen to guide treatment strategy by monitoring EGFR mutation status.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review

Xiaohu Xu, Dong Chen, Xiao Wu, Qi Wang

Summary: This case report describes a pulmonary enteric adenocarcinoma patient with rare co-mutations of EGFR, KRAS, and TP53, being treated with chemotherapy combined with immunotherapy. The combination therapy appears to be effective for this rare type of tumor.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs

Zheng Wang, Xiaoguang Li, Lin Zhang, Yan Xu, Mengzhao Wang, Li Liang, Peng Jiao, Yuanming Li, Shurong He, Jun Du, Lei He, Min Tang, Mingjun Sun, Li Yang, Jing Di, Guanshan Zhu, Lin Li, Dongge Liu

Summary: Sputum cell-free DNA (cfDNA) is a promising sample type for detecting EGFR-sensitizing mutations, especially the challenging p.T790 M mutation in patients with acquired resistance to first or second-generation EGFR-TKIs. The combination of plasma cfDNA testing and sputum cfDNA testing can significantly increase the sensitivity of detecting p.T790 M mutation, providing valuable insights for the application of third-generation EGFR-TKIs in second-line treatment.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma

Wensheng Zhou, Zhichao Liu, Yanan Wang, Yanwei Zhang, Fangfei Qian, Jun Lu, Huimin Wang, Ping Gu, Minjuan Hu, Ya Chen, Zhengyu Yang, Ruiying Zhao, Yuqing Lou, Baohui Han, Wei Zhang

Summary: This study investigated the profile of concomitant alterations in EGFR-mutant LUAD with a size of 3 cm or less and found that TP53 mutation and EGFR amplification were poor prognostic factors for recurrence-free survival.

CANCER MEDICINE (2022)

Add to Collection

Article Cell Biology

Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma

Lingling Zhu, Yanyang Liu, Honglin Gao, Jiewei Liu, Qinghua Zhou, Feng Luo

Summary: This article presents a case of lung cancer in which a patient transformed from LUSC to LUAD and harbored a novel deletion/insertion mutation in EGFR ex20. The patient showed improvement in symptoms after receiving nivolumab plus docetaxel and carboplatin treatment. The study highlights the importance of rebiopsy and molecular retesting after cancer progression.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation

Po-Yen Chen, Chin-Chou Wang, Chien-Ning Hsu, Chung-Yu Chen

Summary: This study compared the relative survival rate of gefitinib, erlotinib, and afatinib in EGFR-mutated advanced lung adenocarcinoma patients in Taiwan. Afatinib showed better overall survival and time to treatment failure outcomes compared to gefitinib and erlotinib, especially in patients with initial brain metastases.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma

Jan Budczies, Martina Kirchner, Klaus Kluck, Daniel Kazdal, Julia Glade, Michael Allgaeuer, Mark Kriegsmann, Claus-Peter Heussel, Felix J. Herth, Hauke Winter, Michael Meister, Thomas Muley, Torsten Goldmann, Stefan Froehling, Martin Wermke, Cornelius F. Waller, Amanda Tufman, Martin Reck, Solange Peters, Peter Schirmacher, Michael Thomas, Petros Christopoulos, Albrecht Stenzinger

Summary: The study found specific immunosuppressive characteristics in ALK- and EGFR-positive lung adenocarcinoma, supporting further clinical evaluation of immune-modulators as partners of immune checkpoint blockade in such tumors. The targeted gene expression profiling is a promising tool to analyze tumor microenvironment characteristics from routine diagnostic lung cancer biopsies.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy

Chiara Corti, Fabio Conforti, Laura Pala, Chiara Catania, Emilia Cocorocchio, Pier Francesco Ferrucci, Giuseppe Curigliano, Paola Queirolo, Tommaso de Pas

Summary: This study investigated the potential activity of avapritinib in mucosal melanoma and thymic carcinoma, two diseases with limited second-line treatment options. The results showed differential activity of avapritinib on KIT exon 17 mutations and potential implications for precision oncology.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely

Summary: EGFR exon 20 insertions are rare in non-small cell lung cancer, with patients showing better outcomes on platinum chemotherapy, lower PD-L1 expression and TMB levels, and less benefit from immune checkpoint inhibitors compared to NSCLC patients without targetable oncogenes.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

Waleed Kian, Petros Christopoulos, Areen A. Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling, Dolev Kahala, Inbal Sara Granot, Dina Levitas, Nir Peled, Laila C. Roisman

Summary: Mobocertinib has shown significant efficacy and good safety profile in patients with EGFRexon20ins. It is a novel TKI that selectively targets EGFRex20ins.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

Xiao Zhang, Huan Han, Jiuzhou Zhao, Xiao Liu, Jianbo Zhang, Rui Sun, Shaomei Li, Baoxing Liu, Hui Zhu, Shuyue Jiao, Xiang Li, Hong Tang

Summary: This study reports a case of a patient with non-small cell lung cancer (NSCLC) with a rare EGFR exon 20 insertion mutation. The patient was treated with furmonertinib and achieved a longer survival period. The results suggest that furmonertinib may be an effective treatment option for patients with EGFR exon 20 insertion mutation.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Oncology

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies

Yi-Long Wu, Egbert F. Smit, Todd M. Bauer

Summary: METex14, a genetic mechanism leading to aberrant activation of the MET receptor in cancer cells, is found in approximately 3-4% of patients with non-small cell lung cancer (NSCLC) and is considered as an independent oncogenic driver in NSCLC. Capmatinib, a highly potent MET inhibitor, has shown promising efficacy in METex14-positive NSCLC patients, leading to its approval by the US FDA for metastatic NSCLC patients harboring METex14.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Editorial Material Oncology

Lung Cancer in the Netherlands

Lizza E. L. Hendriks, Anne-Marie C. Dingemans, Dirk K. M. De Ruysscher, Mieke J. Aarts, Lidia Barberio, Robin Cornelissen, Koen J. Hartemink, Michel van den Heuvel, Ed Schuuring, Hans J. M. Smit, Antonie J. van der Wekken, Egbert F. Smit

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Letter Biochemistry & Molecular Biology

COVID-19 vaccination: the VOICE for patients with cancer

Astrid A. M. van der Veldt, Sjoukje F. Oosting, Anne-Marie C. Dingemans, Rudolf S. N. Fehrmann, Corine GeurtsvanKessel, Mathilde Jalving, Guus F. Rimmelzwaan, Pia Kvistborg, Christian U. Blank, Egbert F. Smit, Valery E. E. P. Lemmens, T. Jeroen N. Hiltermann, Marion P. G. Koopmans, Anke L. W. Huckriede, Nynke Y. Rots, Cecile A. C. M. van Els, Debbie van Baarle, John B. A. G. Haanen, Elisabeth G. E. de Vries

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy

Stefano Trebeschi, Zuhir Bodalal, Thierry N. Boellaard, Teresa M. Tareco Bucho, Silvia G. Drago, Ieva Kurilova, Adriana M. Calin-Vainak, Andrea Delli Pizzi, Mirte Muller, Karlijn Hummelink, Koen J. Hartemink, Thi Dan Linh Nguyen-Kim, Egbert F. Smit, Hugo J. W. L. Aerts, Regina G. H. Beets-Tan

Summary: The study demonstrated that artificial intelligence can be used to extract more prognostic information from chest CT scans of lung cancer patients, outperforming 2D tumor growth criteria. This AI technology can accurately predict overall survival and clinical benefit, independently of other factors. Further research is needed to explore the application of this technique beyond thoracic imaging.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer

Anna-Larissa N. Niemeijer, Daniela E. Oprea-Lager, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Berlinda J. de Wit-van der Veen, Idris Bahce, Danielle J. Vugts, Guus A. M. S. van Dongen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen

Summary: This study investigated the response of NSCLC patients to pembrolizumab monotherapy and the uptake of Zr-89-pembrolizumab in tumors, finding that patients with higher uptake had better responses to treatment. Although no significant correlation was found with PD-L1 or PD-1 immunohistochemistry, the injection of Zr-89-pembrolizumab was deemed safe in the study.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer

Jasper Smit, Frank J. Borm, Anna-Larissa N. Niemeijer, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Daniela E. Oprea-Lager, Danielle J. Vugts, Guus A. M. S. van Dongen, Berlinda J. de Wit-van der Veen, Erik Thunnissen, Egbert F. Smit, Adrianus J. de Langen

Summary: Zr-89-durvalumab is safe and may provide a better way to assess tumor PD-L1 expression in NSCLC patients treated with immunotherapy. However, further research is needed to validate its utility.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer

Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne

Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik

Summary: Tepotinib demonstrated durable clinical activity in patients with METex14 skipping non-small cell lung cancer and consistent efficacy and manageable safety profile across different subgroups.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Egbert F. Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M. Tho, Xiuning Le, Julien Mazieres, How S. Hin, Masahire Morise, Viola W. Zhu, Daniel Tan, Kristina H. Holmberg, Barbara Ellers-Lenz, Svenja Adrian, Sabine Brutlach, Karl M. Schumacher, Niki Karachaliou, Yi-Long Wu

Summary: Combining osimertinib with MET inhibitor like tepotinib could potentially overcome resistance driven by MET amplification in NSCLC patients, and the ongoing study INSIGHT 2 aims to evaluate the efficacy and safety of this combination therapy for patients with acquired resistance to osimertinib due to MET amplification.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis

Pieter J. M. Joosten, Chris Dickhoff, Vincent van der Noort, Maarten Smeekens, Rachel C. Numan, Houke M. Klomp, Judi N. A. van Diessen, Jose S. A. Belderbos, Egbert F. Smit, Kim Monkhorst, Jan W. A. Oosterhuis, Michel M. van den Heuvel, Max Dahele, Koen J. Hartemink

Summary: In patients with Stage IIIA NSCLC, those with a large tumor volume and adenocarcinoma who were selected for trimodality treatment showed better outcomes compared to those receiving chemoradiotherapy.

INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY (2022)

Add to Collection

Article Oncology

Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design

Gregory J. Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Egbert F. Smit, Anne S. Tsao, Ann Alcasid, Tiziana Usari, Paul S. Wissel, Keith D. Wilner, Bruce E. Johnson

Summary: BRAF(V600) mutations occur in 1-2% of NSCLC patients, and combination therapy with BRAF and MEK inhibitors has shown potential efficacy. The ongoing PHAROS trial aims to evaluate the antitumor activity and safety of encorafenib plus binimetinib in patients with metastatic BRAF(V600)-mutant NSCLC.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer

Gregory J. Riely, Egbert F. Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S. Ramalingam, Anne Tsao, Melissa Johnson, Francesco Gelsomino, Raymond Esper, Ernest Nadal, Michael Offin, Mariano Provencio, Jeffrey Clarke, Maen Hussain, Gregory A. Otterson, Ibiayi Dagogo-Jack, Jonathan W. Goldman, Daniel Morgensztern, Ann Alcasid, Tiziana Usari, Paul Wissel, Keith Wilner, Nuzhat Pathan, Svitlana Tonkovyd, Bruce E. Johnson

Summary: The combination of encorafenib and binimetinib showed clinical efficacy and acceptable safety in patients with BRAF(V600E)-mutant metastatic NSCLC.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne

Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu

Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Respiratory System

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Rolof G. P. Gijtenbeek, Vincent van der Noort, Joachim G. J. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D. J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E. E. M. van den Borne, Harry J. M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken

Summary: This study found that in patients with EGFR-mutated NSCLC, intercalated erlotinib with cisplatin-pemetrexed chemotherapy significantly prolonged progression-free survival compared to erlotinib monotherapy, but at the cost of increased toxicity.

ERJ OPEN RESEARCH (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.